Questions about gemcitabine dose rate: Answered or unanswered?

Journal of Clinical Oncology

Volumn 25, Issue 36, 2007, Pages 5691-5694

  Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; GEMCITABINE; OXALIPLATIN; ROFECOXIB;

AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG TOLERABILITY; EDITORIAL; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS;

EID: 37649008624     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.6879     Document Type: Editorial

References (27)

1. Gandhi V, Plunkett W: Modulatory activity of 2′,2′- difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50:3675-3680, 1990
2. Grunewald R, Kantarjian H, Keating MJ, et al: Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823-6826, 1990
3. Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
4. Grunewald R, Abbruzzese JL, Tarassoff P, et al: Saturation of 2′,2′-difluorodeoxycytidine 5-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258-262, 1991
5. Grunewald R, Kantarjian H, Du M, et al: Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406-413, 1992
6. Gandhi V, Plunkett W, Du M, et al: Prolonged infusion of gemcitabine: Clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 20:665-673, 2002
7. Fossella FV, Lippman SM, Shin DM, et al: Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung caner. J Clin Oncol 15:310-316, 1997
8. Plunkett W, Huang P, Searcy CE, et al: Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 23:3-15, 1996
9. Tempero M, Plunkett W, Ruiz Van Haperen V, et al: Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408, 2003
10. Poplin E, Levy DE, Berlin J, et al: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 24, 2006 (suppl; abstr 4004)
11. Liebes L, Levy DE, Poplin E, et al: Gemcitabine (G) plasma and intracellular pharmacokinetics in E6201: Greater metabolite levels using fixed dosing rate (FDR) delivery. J Clin Oncol 24, 2006 (suppl; abstr 2024)
12. Guan Z, Wang Y, Maoleekoonpairoj S, et al: Prospective randomized phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer 89:1865-1869, 2003
13. Cappuzzo F, Novello S, De Marinis F, et al: A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer 52:319-325, 2006
14. Patel SR, Gandhi V, Jenkins J, et al: Phase II Clinical investigation of gemcitabine in advanced soft-tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483-3489, 2001
15. Ceribelli A, Gridelli C, De Marinis F, et al: Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: A randomized phase II study of two different schedules in combination with cisplatin. Cancer 98:337-343, 2003
16. Pereira JR, Fein L, Del Giglio A, et al: Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small-cell lung cancer. Lung Cancer 58:80-87, 2007
17. Soo RA, Wang LZ, Tham LS, et al: A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 17:1128-1133, 2006
18. Wang LR, Huang MZ Zhang GB, et al: Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 60:601-607, 2007
19. Comella P, Putzu C, Massidda B, et al: Intra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small-cell lung cancer patients: A Southern Italy Cooperative Oncology Group randomized phase II trial. Lung Cancer 56:263-271, 2007
20. Gridelli C, Gallo C, Ceribelli A, et al: Factorial phase III randomized trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: The GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 8:500-512, 2007
21. Grimison P, Galettis P, Manners S, et al: A randomized crossover study evaluating the effect of gemcitabine infusion dose rate: Evidence of autoinduction of gemcitabine accumulation. J Clin Oncol 25:5704-5709, 2007
22. Eisbruch A, Shewach DS, Bradford CR, et al: Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study. J Clin Oncol 19:792-799, 2001
23. Zhou B, Mi S, Mo X, et al: Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells. Anticancer Res 22:1369-1377, 2002
24. Yen Y, Chow W, Leong L, et al: Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: A California cancer consortium trial. Cancer Chemother Pharmacol 50:353-359, 2002
25. Yen Y, Margolin K, Doroshow J, et al: A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 54:331-342, 2004
26. van der Donk WA, Yu G, Perez L, et al: Detection of a new substrate-derived radical during inactivation of ribonucleotide reductase from Escherichia coli by gemcitabine 5′-diphospahte. Biochemistry 37:6419-6426, 1998
27. Xu H, Faber C, Uchiki T, et al: Structures of eukaryotic ribonucleotide reductase I define gemcitabine diphosphate binding and subunit assembly. Proc Natl Acad Sci U S A 103:4028-4033, 2006